Tag: cetuximab

Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. The US Food and Drug Administration (FDA) has granted Eli Lilly’s request to revoke emergency use authorization for the COVID-19 monoclonal antibody therapy bamlanivimab when used as a monotherapy, saying the evidence indicates that it is likely not effective against currently circulating

NEW YORK (Reuters Health) – Long-term glucocorticoid (GC) users see greater gains in spine bone-mineral density when treated with the monoclonal antibody denosumab versus oral alendronate, a small clinical trial shows. The drug also proved superior at lowering bone-turnover markers at 12 months, researchers in Hong Kong report in Bone. “Denosumab may be considered as